Quick answers

What is Cerebrolysin and what is it used for in research?
Cerebrolysin is classified within the Cognitive & Nootropic group. Peptide preparation with neurotrophic-factor-like activity. Registered in Europe/Asia for stroke and dementia. Research applications focus on the pathways outlined below. All references on this page describe published research only, Cerebrolysin is supplied for in-vitro and laboratory use, not for human consumption.
How does Cerebrolysin work?
Primary mechanism: Porcine-derived neuropeptide mixture; neurotrophic and neuroprotective. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for Cerebrolysin remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical Cerebrolysin research dose?
Published research protocols for Cerebrolysin describe per-dose ranges of 5–30 mL IM/IV, with a weekly total near Per cycle, administered daily for 10–20 days. Typical cycle: 2× per year. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy Cerebrolysin in Thailand?
Cerebrolysin is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk, no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can Cerebrolysin be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

What is Cerebrolysin?

Cerebrolysin is a research peptide in the Cognitive & Nootropic class. Porcine-derived neuropeptide mixture; neurotrophic and neuroprotective. It is studied at per-dose ranges of 5–30 mL IM/IV (Per cycle weekly), administered daily for 10–20 days over cycles of 2× per year. Supplied in Thailand by Thailand Peptides, Bangkok-based, research use only.

Peptide preparation with neurotrophic-factor-like activity. Registered in Europe/Asia for stroke and dementia.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does Cerebrolysin work?

Cerebrolysin is a standardised, enzymatically produced mixture of porcine-brain-derived low-molecular-weight peptides and free amino acids. Its pharmacology mimics neurotrophic-factor (BDNF, NGF, GDNF) signalling in preclinical models, with effects on neuronal survival, synaptic plasticity, and neuroprotection under ischaemic insult. It is registered in the EU, Russia, China, and other Asian markets for stroke and dementia indications.

Receptor binding affinity and post-receptor signalling for Cerebrolysin remain areas of active investigation; several proposed effects within the Cognitive & Nootropic class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

Cerebrolysin pharmacokinetics

Half-life
Product supplied as a mixture of low-molecular-weight peptides and free amino acids; individual component half-lives vary.
Bioavailability
IM and IV routes are the registered administration pathways; oral route not used.
Route of administration
Intramuscular or slow IV infusion daily for 10–20 days, typically 2× per year.
Metabolic clearance
Component peptides metabolised via standard proteolytic pathways.

Cerebrolysin research timeline

  1. 1980s Initial registration and clinical use in Central/Eastern Europe for stroke and dementia.
  2. 2010s Multiple Phase 3 trials in acute ischaemic stroke and vascular dementia published.

Cerebrolysin dosage & protocol

Reference protocol for Cerebrolysin (research context only, drawn from published literature):

  • Per dose: 5–30 mL IM/IV
  • Weekly total: Per cycle
  • Frequency: Daily for 10–20 days
  • Cycle: 2× per year

Cerebrolysin injection & handling

Reconstitution
Supplied in pre-filled ampoules of 5 mL, 10 mL, or larger; no reconstitution required.
Storage
Stored below 25 °C, protected from light.
Sites used in the research literature
Intramuscular (deep gluteal/thigh) for volumes up to 5 mL; larger volumes given as slow IV infusion per product monograph.

Handling notes reflect methods used in published research protocols, not medical dosing guidance.

Order Cerebrolysin
Ready to order? WhatsApp the Bangkok research desk, pricing and availability confirmed within the chat.
Ask about Cerebrolysin ≥98% HPLC purity · supplier COA on file · Bangkok-based

Stacking Cerebrolysin

Commonly referenced pairing with Cerebrolysin: Semax. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a Cerebrolysin stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Status epilepticus. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Further reading

Compare Cerebrolysin with: Selank Semax

Citations

  1. Muresanu DF, et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016. PMID: 26564102
  2. Heiss WD, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA). Stroke. 2012. PMID: 22282884

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.